Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18934371 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL18926560 | 0.95 | GAA (0.50) | ALDH1A1KMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL18926554 | 0.94 | CA2 (0.53) | ALDH1A1KMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL7723972 | 0.92 | CNR2 (0.54) | ALDH1A1KMT2AMEN1CYP2C9CYP2C19 | |
| SCHEMBL4793354 | 0.92 | FKBP1A (0.52) | ALDH1A1KMT2AMEN1CYP3A4CYP2C9 | |
| SCHEMBL7028389 | 0.92 | CNR2 (0.50) | ALDH1A1CYP3A4CYP2C9CYP2C19PSMD10 | |
| SCHEMBL8780852 | 0.91 | FKBP1A (0.53) | ALDH1A1KMT2APSMD10CNR2FKBP1A | |
| SCHEMBL13649253 | 0.91 | ENPP1 (0.52) | ALDH1A1KMT2AMEN1CA2CA1 | |
| SCHEMBL11204014 | 0.90 | BCHE (0.51) | ALDH1A1KMT2AMEN1PSMD10CA2 | |
| SCHEMBL10557145 | 0.90 | CNR2 (0.46) | PSMD10CNR2FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561585-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | Sanifit Therapeutics S.A. (ES) | 2025-06-04 | — | — | EP | disclosed |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | VIFOR (INTERNATIONAL) LTD. (CH) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023359-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION | SANIFIT THERAPEUTICS, S.A. (ES) | 2024-02-01 | — | — | WO | disclosed |
| EP-4284809-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022162206-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | SANIFIT THERAPEUTICS, S.A. (ES) | 2022-08-04 | — | — | WO | disclosed |
| EP-4036097-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | Sanifit Therapeutics S.A. (ES) | 2022-08-03 | — | — | EP | disclosed |
| EP-1626961-B1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RES INST OF BIOSCIENCE (KR) | 2011-11-02 | — | — | EP | disclosed |
| US-7846963-B2 | 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-12-07 | — | — | US | disclosed |
| US-20100286207-A1 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-11-11 | — | — | US | disclosed |
| US-7723376-B2 | 2-oxo-heterocyclic compounds and pharmaceutical compositions | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2010-05-25 | — | — | US | disclosed |
| CN-1822832-A | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2006-08-23 | — | — | CN | disclosed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | disclosed |
| CN-1791579-A | Novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RES INST OF BIOSCIENCE (KR) | 2006-06-21 | — | — | CN | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | disclosed |
| EP-0051917-B1 | BENZOFURAN ETHANOLAMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND THEIR USE IN MEDICINE | BEECHAM GROUP PLC (GB) | 1986-02-19 | — | — | EP | disclosed |
| US-4432993-A | 2-(2-BENZOFURANYL)ETHANOLAMINE | BEECHAM GROUP LIMITED (GB) | 1984-02-21 | — | — | US | disclosed |
| EP-0051917-A1 | Benzofuran ethanolamine derivatives, processes for their preparation, and their use in medicine | BEECHAM GROUP PLC (GB) | 1982-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286207-A1 | Novel 2-Oxo-Heterocyclic Compounds And The Pharmaceutical Compositions Comprising The Same | NOD2, BMP2, NOD1 | ALDH1A1 1362/4885KMT2A 4570/4885MEN1 3246/4885 |
| US-20240109924-A1 | IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS | IPO4, TPX2, IPO9 | ALDH1A1 4700/4885KMT2A 4555/4885MEN1 2984/4885 |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | ALDH1A1 519/4885KMT2A 1854/4885MEN1 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.